Scientifically prepared knowledge on peptide structures, mechanisms of action, and clinical studies.
The real NEJM Phase 2 numbers for retatrutide: weight loss at 24 and 48 weeks, dose escalation – and why forum reports aren't directly comparable.
Real dosing data from BPC-157 animal studies – from 10 µg/kg in tendon healing to the lack of human data.
Dry powder vs. reconstituted solution: what practice and available data show about storing research peptides – including the tesamorelin exception.
The real trial numbers from STEP-1, SURMOUNT-1, and the retatrutide trials, side by side – and why a direct comparison still has limits.
Functional improvement from day 4, full tendon integrity after 14 days: what published animal models actually show about the BPC-157 timeline.
A GHRH analog meets a selective ghrelin receptor agonist: the mechanistic logic behind the combination – and why no study exists for this exact pairing.
A detailed comparison of molecular mechanisms of action of GLP-1, GIP, and Glucagon receptor agonists in current studies.
How pentadecapeptide BPC-157 and the thymosin beta-4 analog TB-500 address tissue regeneration via different mechanisms in preclinical models.
The tripeptide-copper complex and its role in collagen cross-linking, gene expression, and tissue regeneration.
Why Ipamorelin shows higher receptor selectivity compared to older GHRPs – and how GHRH analogs like Sermorelin and Tesamorelin differ.
Why NAD+ is not a peptide but a coenzyme – and what current research shows about aging and metabolism.
How Melanotan I, Melanotan II, and PT-141 differ in receptor selectivity – and why only part of this drug class is FDA approved.
From approved drugs to WADA-listed compounds – an overview of the widely varying regulatory status of common research peptides.